相关实验视频

Updated: Jul 17, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

在转移性细胞癌中GITR的预后和预测意义

O Y Balçık¹, D Akın, G S Ceylan

¹Medical Oncology, Mardin Training and Research Hospital, Mardin, Turkey.

European review for medical and pharmacological sciences

|September 5, 2023

概括

在转移性细胞癌 (RCC) 患者中,高葡萄糖皮质醇诱导的TNF受体 (GITR) 水平与改善无进展生存 (PFS) 相相关. 这表明GITR可能作为预后和预测标志物,特别是在用nivolumab治疗的患者身上.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物标志物发现发现

背景情况:

转移性细胞癌 (RCC) 发病率正在上升,免疫检查点抑制剂提供了新的治疗途径.
葡萄糖皮质醇诱导瘤亡因子受体 (GITR) 是T细胞和调节性T细胞 (Tregs) 上的共刺激分子,影响抗瘤免疫力.
GITR在抑制抑制Treg功能中的作用表明它有可能成为抗癌治疗点.

研究的目的:

在转移性RCC患者中调查GITR,瘤透性淋巴细胞 (TILs:CD4+CD8) 和FOXP3的预后和预测价值.
评估GITR表达与患者结果之间的关联,包括无进展生存率 (PFS) 和整体生存率 (OS).
确定GITR表达是否可以预测转移性RCC患者对尼沃卢马布治疗的反应.

主要方法:

对41名病理确诊的转移性RCC患者的回顾性分析,这些患者在2016年至2021年期间被诊断为RCC.
免疫组织化学 (IHC) 用于评估瘤活检或瘤切除标本中的GITR,CD4,CD8和FOXP3表达.
收集和分析了临床病理学数据和实验室测试结果.

主要成果:

整个队列中,PFS的中位数为10.5个月,OS的中位数为13.9个月.
与低GITR表达 (7.9个月) (p=0.003) 患者相比,高GITR表达的患者的PFS中位数显著更长 (18.9个月) (p=0.003).
在接受尼沃卢马布治疗的患者中,高GITR表达与明显改善的中位数PFS (15.7个月) 与低GITR (5.7个月) (p=0.026) 相比.

结论:

在转移性RCC中,高GITR表达与更好的PFS有关.
在转移性RCC中,高GITR表达似乎预测了对尼沃卢马布治疗的良好反应.
作为转移性RCC的预后和预测生物标志物,GITR具有前性,在前性研究中需要进一步验证.

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...